Iovance Biotherapeutics Statistics
Share Statistics
Iovance Biotherapeutics has 304.78M shares outstanding. The number of shares has increased by 18.6% in one year.
| Shares Outstanding | 304.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 8.46% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 246.81M |
| Failed to Deliver (FTD) Shares | 424.24K |
| FTD / Avg. Volume | 7.05% |
Short Selling Information
The latest short interest is 59.73M, so 19.6% of the outstanding shares have been sold short.
| Short Interest | 59.73M |
| Short % of Shares Out | 19.6% |
| Short % of Float | 24.19% |
| Short Ratio (days to cover) | 13.08 |
Valuation Ratios
The PE ratio is -4.31 and the forward PE ratio is -11.82.
| PE Ratio | -4.31 |
| Forward PE | -11.82 |
| PS Ratio | 1607.75 |
| Forward PS | 5.2 |
| PB Ratio | 3.27 |
| P/FCF Ratio | -4.98 |
| PEG Ratio | n/a |
Enterprise Valuation
Iovance Biotherapeutics Inc. has an Enterprise Value (EV) of 1.87B.
| EV / Earnings | -4.22 |
| EV / Sales | 1574.93 |
| EV / EBITDA | -4.38 |
| EV / EBIT | -4.07 |
| EV / FCF | -4.88 |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.79 |
| Quick Ratio | 2.7 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.48 |
| Cash Flow / Debt | -41.22 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -69.19%.
| Return on Equity (ROE) | -0.76% |
| Return on Assets (ROA) | -0.57% |
| Return on Capital (ROIC) | -69.19% |
| Revenue Per Employee | 2.13K |
| Profits Per Employee | -797.19K |
| Employee Count | 557 |
| Asset Turnover | 0 |
| Inventory Turnover | 1.04 |
Taxes
| Income Tax | -3.48M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 0.64% in the last 52 weeks. The beta is 0.59, so Iovance Biotherapeutics 's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | 0.64% |
| 50-Day Moving Average | 9.69 |
| 200-Day Moving Average | 10.52 |
| Relative Strength Index (RSI) | 36.22 |
| Average Volume (20 Days) | 6.02M |
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of $1.19M and earned -$444.04M in profits. Earnings per share was $-1.89.
| Revenue | 1.19M |
| Gross Profit | -9.57M |
| Operating Income | -460.56M |
| Net Income | -444.04M |
| EBITDA | -427.43M |
| EBIT | -460.56M |
| Earnings Per Share (EPS) | -1.89 |
Balance Sheet
The company has $114.89M in cash and $75.86M in debt, giving a net cash position of $39.03M.
| Cash & Cash Equivalents | 114.89M |
| Total Debt | 75.86M |
| Net Cash | 39.03M |
| Retained Earnings | -2.01B |
| Total Assets | 991.12M |
| Working Capital | 380.52M |
Cash Flow
In the last 12 months, operating cash flow was -$361.82M and capital expenditures -$22.29M, giving a free cash flow of -$384.11M.
| Operating Cash Flow | -361.82M |
| Capital Expenditures | -22.29M |
| Free Cash Flow | -384.11M |
| FCF Per Share | -1.63 |
Margins
Gross margin is -804.54%, with operating and profit margins of -38.73K% and -37.35K%.
| Gross Margin | -804.54% |
| Operating Margin | -38.73K% |
| Pretax Margin | -37.64K% |
| Profit Margin | -37.35K% |
| EBITDA Margin | -35.95K% |
| EBIT Margin | -38.73K% |
| FCF Margin | -32.31K% |
Dividends & Yields
IOVA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.14% |
| FCF Yield | -16.1% |
Analyst Forecast
The average price target for IOVA is $23, which is 193.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 193.7% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Sep 26, 2013. It was a backward split with a ratio of 1:100.
| Last Split Date | Sep 26, 2013 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | 3.03 |
| Piotroski F-Score | 4 |